Experienced CEO takes over
By appointing Olav Hellebø as Chief Executive Officer, biotechnology company Exonate Ltd. aims to accelerate the clinical development of its lead candidate for diabetic eye disease.
ADVERTISEMENT
About Maren Kühr
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 284 entries already.
Entries by Maren Kühr
The connective matrix: ELRIG’s role in the drug discovery ecosystem
Drug discovery depends on more than breakthrough science alone. Progress increasingly emerges from connected ecosystems where academia, biotech, pharma, CROs and technology providers can openly exchange ideas, challenge assumptions and accelerate innovation together.
Theranostics as potential novel therapeutic pillar in oncology
See-and-Treat Concept using Radioactive Smart Probes: Professor Rudolf Werner provides an overview of established and future indications in clinical practice, highlighting advances in theranostics and their growing impact on precision oncology.
Europe’s imperative: Early-stage investors and company creation
European biotech is seeing both encouraging momentum and challenges. Innovation from European academia continues to inspire therapeutic concepts.
Drug delivery nanogel to transform medical devices
CM4Cure is focused on substantially improving patient outcomes, improving medical device performance by incorporating drug delivery. Our technology redefines medical device coatings – converting passive barriers into active systems via a unique nanogel able to deliver multiple APIs. Initially focused on iv catheters – >2bn are used globally pa – the platform has potential to reduce infection and thrombosis across a swathe of medical devices
Next-gen oligonucleotides to transform patient care
Secarna Pharmaceuticals is redefining the discovery and development of oligonucleotide therapeutics to address hard-to-treat disorders. The Company is planning to raise a Series A to advance its lead oncology asset, SECN-15, into Phase 1/2. Secarna is supported by global partnerships that validate their expertise and accelerate development.
Biotechnology expert joins CDMO
Dr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the Polish company Rezon Bio.
MS expert takes the helm
Erik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s scientific strategy.
Standing Together in Uncertain Times
Chemspec Europe returned to Cologne between 6-7 May 2026, drawing 4,238 attendees from 60 nations and 454 exhibitors from 28 countries, an increase from last year’s event.
The European CDMO Model, Powering Biologics Innovation
Europe continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.